The effectiveness of the drug Vessel Due F in patients with diabetes with nonproliferative and preproliferative diabetic retinopathy


Cite item

Full Text

Abstract

The results of the study of clinical significance of glycosaminoglycans (sulodeksid - Vessel Due F) use in combination with laser coagulation of the retina for the prevention and treatment of primary and expressed stages of diabetic retinopathy (DR) in 191 patients with diabetes mellitus (DM) are presented. According to the analysis of the dynamics of ocular fundus state in patients with diabetes for 2 years after treatment, sulodeksid administration reduces microvascular abnormalities in patients with early changes in the ocular fundus. The laser coagulation in combination with the sulodeksid administration provides a persistent positive effect on the course of the disease in diabetic patients with nonproliferative and preproliferative DR. Refresher several courses of laser coagulation in combination with use of Vessel Due F are necessary to achieving the process stabilization in diabetic patients with marked changes in the ocular fundus.

References

  1. Шестакова М.В., Дедов И.И. Современные подходы к профилактике и лечению диабетической нефропатии // Терапевтический архив. 1994. № 6. С. 75-78.
  2. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5):766-85.
  3. Prior MJ, Prout T, Miller D, et al. C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Ann Epidemiol 1993;3(1):9-17.
  4. Rubbi F, Canova N. Retinal vein occlusion: Study of treatment with sulodexide. Eur J Clin Res 1993:19-27.
  5. Rubbi F, et al. The effects of sulodexide on diabetic retinopathy. Minerva Cardioangio 2000;48(Suppl. 9).
  6. Миленькая Т.М., Терентьев В.С., Щербачева Л. Диабетическая ретинопатия, диагностика, лечение // РМЖ. 1998. Т. 6. № 12.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies